US FDA approves Genfit and Ipsen's liver disease drug
10/06/2024 22:02
June 10 (Reuters) - The U.S. Food and Drug Administration has approved French drugmakers Ipsen IPN.PA and Genfit's GNFT.PA drug to treat a chronic inflammatory liver disease, Ipsen said on Monday. (Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Genfit SA
See all newsFrance's Genfit H1 revenue falls due to absence of milestone payments
French and Benelux stocks-Factors to watch on September 15
Brief: Genfit SA - Advances Nangibotide In Phase 2 Clinical Investigation In Aclf
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Genfit March 31 Cash And Cash Equivalents EUR 136.1 Million